GLP-1 weight loss on TikTok: what the scale won't tell you

What did @ashleydurden05 actually say?

Honestly, not much, at least not medically. The transcript is song lyrics, not health claims. What the video does communicate is a specific behavioral ritual: weekly weigh-ins paired with weekly GLP-1 injections, framed as a motivational Monday routine. The caption promises a two-week weight loss update on tirzepatide.

The implicit claims here are worth taking seriously even if they were never spoken aloud. The video normalizes self-weighing on a fixed schedule, treats the injection day as a social media event, and sets up a two-week results expectation. That's a specific framework for how to experience GLP-1 therapy, and it's worth checking against what the evidence actually shows about weighing frequency, early expectations, and patient experience on these medications.

Does the science back this up?

The weekly weigh-in habit has reasonable support. The evidence on self-monitoring weight is genuinely solid, and weekly is probably the sweet spot.

A 2019 study by Larsen et al. in Obesity found that daily or weekly self-weighing was associated with better weight loss outcomes compared to monthly or no monitoring, with weekly weighing showing fewer negative psychological effects than daily. That matters because GLP-1 medications cause non-linear weight loss, meaning the scale can stall or fluctuate even when the drug is working. A 2023 trial published in The New England Journal of Medicine by Jastreboff et al. on tirzepatide (the SURMOUNT-1 trial) showed mean weight reduction of 20.9 percent at 72 weeks for the highest dose group, but the trajectory is not a straight line downward week over week. Expecting visible drops every single weigh day is a setup for unnecessary frustration.

Two weeks is also an extremely short window for tirzepatide. The drug is typically titrated over several months, starting at 2.5 mg weekly before moving up. Major metabolic effects accumulate over time, not in a fortnight.

What did they get wrong (or right)?

The ritual itself is not wrong. Pairing a consistent behavior, the weekly shot, with a consistent check-in, the weigh-in, is actually smart habit design. Behavioral research on implementation intentions (Gollwitzer, 1999, American Psychologist) supports linking health behaviors to specific cues. Monday shot day as a cue for Monday weigh day is a reasonable structure.

What gets shakier is the implied expectation of visible results after two weeks. At 2.5 mg tirzepatide, the starting dose, appetite suppression is modest. Jastreboff et al. (2022, NEJM) showed that most significant weight loss in SURMOUNT-1 accumulated after dose escalation, which typically does not happen until week 5 or later. Framing week two as a meaningful milestone can distort patient expectations in ways that lead to early discontinuation, which is a real problem with GLP-1 therapy. A 2023 analysis in JAMA Health Forum by Shaaban et al. found that more than half of GLP-1 patients discontinue within 12 months, often due to unmet early expectations.

The misspelling of semaglutide as "semiglutide" in the hashtags is worth noting. It is a minor error but it is the kind of thing that makes it harder for people searching for accurate information to find this content.

What should you actually know?

If you are on tirzepatide or semaglutide, the two-week mark is almost certainly too early to judge the medication. That is not a reason to quit, it is just the pharmacological reality of how these drugs work.

Weekly weigh-ins are a reasonable tool, but context matters. Weight fluctuates by 1 to 3 pounds day to day based on water retention, food volume, hormonal cycles, and bowel habits, none of which reflect fat loss. The trend over 4 to 8 weeks is more informative than any single Monday reading.

GLP-1 medications are not a fast result. The SURMOUNT-1 data showed the most dramatic losses between weeks 20 and 72. Patients who stick with titration, manage side effects, and adjust their expectations accordingly get the best outcomes. Social media timelines for these drugs tend to compress the timeline in ways that set people up for disappointment.

If you are considering tirzepatide or semaglutide, those decisions should go through a licensed provider who can assess your full medical history, not a TikTok comment section. Compounded versions of these drugs are not equivalent to FDA-approved brand-name formulations, and dosing should never be self-directed based on what you see working for someone online.